FUNDAMENTALS
EdgeFII/DII
TORNTPHARMTorrent Pharmaceuticals
₹4,689.50+1.70%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
TORNTPHARMNSE · EquityPharmaceuticals

Torrent Pharmaceuticals

ISIN
INE685A01028
Instrument key
NSE_EQ|INE685A01028
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹4,689.50+78.50 · +1.70%
Day rangecircuit ₹4,220.60 – ₹5,158.40
4,611.20
4,689.50

as of 22/11/2026, 1:35:45 pm

Open
₹4,618.90
Day high
₹4,689.50
Day low
₹4,611.20
Prev. close
₹4,611.00
Volume
2.00 L
VWAP
₹4,659.46

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 5Y
+208.92%
1,518.05 → 4,689.50
Period high
₹5,250.00
3/8/2026
Period low
₹1,242.05
9/5/2022
From high
-10.68%
+277.56% from low
Avg volume
17.01 L
44.39 Cr total
Volatility · ann.
21.6%
261 candles · 147 up / 114 down
16 Nov 2026O 4,708.50H 4,732.30L 4,592.60C 4,689.50Vol 12.02 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data261 rows of open, high, low, close and volumeShowHide
16 Nov 20264,708.504,732.304,592.604,689.50-0.40%139.7012.02 L
9 Nov 20264,812.504,835.004,655.104,670.00-2.96%179.9012.81 L
2 Nov 20264,636.504,800.004,553.004,773.00+2.94%247.0019.99 L
26 Oct 20264,561.104,672.004,466.804,613.40+1.15%205.2019.61 L
19 Oct 20264,551.204,650.704,470.404,524.40-0.59%180.3010.71 L
12 Oct 20264,657.104,682.004,550.404,558.90-2.11%131.6012.73 L
5 Oct 20264,767.304,795.004,590.004,656.90-2.32%205.0014.72 L
28 Sept 20264,980.004,996.504,717.304,767.30-4.27%279.2018.84 L
21 Sept 20264,860.005,010.004,848.504,988.50+2.64%161.5015.58 L
14 Sept 20264,931.004,959.504,755.504,840.00-1.85%204.0019.43 L

Historical price and volume data · Showing 1–10 of 261

1 / 27

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

85.15
Company
85.15
Sector
-45.69

Worse than sector by 286%

P/B

Price ÷ book value per share

9.73
Company
9.73
Sector
4.2

Worse than sector by 132%

ROA

Net income ÷ total assets

4.7%
Company
4.7%
Sector
1.19%

Better than sector by 295%

ROE

Net income ÷ shareholders' equity

11.42%
Company
11.42%
Sector
-0.4%

Better than sector by 2955%

ROCE

EBIT ÷ capital employed

11.37%
Company
11.37%
Sector
15.44%

Worse than sector by 26%

Quick Ratio

Liquid assets ÷ current liabilities

0.75
Company
0.75
Sector
4.78

Worse than sector by 84%

EV/EBITDA

Enterprise value ÷ EBITDA

34.12
Company
34.12
Sector
22.9

Worse than sector by 49%

04/Business

About the company

Sector: Pharmaceuticals

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain management, gynecology, and dermatology. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its Anti-diabetic products include Gliclazide 80 mg, Tablets, Gliclazide 30 mg, Tablets, Glimepiride 1, 2, 3, 4 mg, Tablets, and others. Its dermatologic therapy products include Macrotor, Ahaglow S Facewash, Fungicide Lotion, Hairjoy 2%, New Dewsoft Cream, Lookbrite 20GMS, Cortaz NC, Dermanex, and others. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim.

Sector market cap (INR)
₹1,78,727 Cr

reported in crore

Sector market cap (USD)
$19.86B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹4,969 Cr
+1.22% vs Jun 2026
Net profit · Sep 2026
₹534 Cr
-5.65% vs Jun 2026
Operating margin
14.8%
was 14.9%
Revenue CAGR · 4p
14.7%
profit -5.6% · op -3.3%
Filed order
Revenue4,9694,9094,1803,290
Revenue growthreported1.2%17.4%27.1%—
Operating profit737733529814
Operating profit growthreported0.6%38.6%-35.0%—
Operating marginderived14.8%14.9%12.7%24.7%
Net profit534566364635
Net profit growthreported-5.7%55.5%-42.7%—
Net marginderived10.7%11.5%8.7%19.3%
EPS — basic₹/share, annual——63.92—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue13,98011,51610,7289,620
Other Income-94235845
Total Revenue13,88611,53910,7869,665
Total Expenses10,9258,8428,5227,818
Profit Before Tax2,8722,6732,3521,847
Tax734762696602
Profit After Tax2,1381,9111,6561,245
EPS - Basic63.9256.4748.9436.79
EPS - Diluted63.9256.4748.9436.79

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹44,312 Cr
+195.62% YoY
Total liabilities
₹26,727 Cr
Net worth
₹17,585 Cr
Liabilities ÷ assets
60.3%
lower means a lighter balance sheet
Filed order
Total assets44,31214,99015,06115,012
Total liabilities26,7277,3998,2048,814
Net worthderived17,5857,5916,8566,198
Liabilities ÷ assetsderived60.3%49.4%54.5%58.7%
Asset growthderived195.6%-0.5%0.3%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets34,9209,3679,4499,698
Current Assets9,3925,6235,6115,314
Total Assets44,31214,99015,06115,012
Current Liabilities8,3434,7175,4255,447
Net Current Asset1,049905186-134
Non-Current Liabilities18,3842,6822,7793,366
Equity Capital17,5857,5916,8566,198
Total Equity & Liabilities44,31214,99015,06115,012

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹3,023 Cr
+16.93% YoY
Investing
-₹12,712 Cr
Financing
₹10,151 Cr
Free cash flow
-₹9,690 Cr
operating + investing
Filed order
Operating activities3,0232,5853,2662,368
Operating changereported16.9%-20.9%37.9%—
Investing activities-12,712-540-168-2,415
Investing changereported-2253.9%-221.7%93.0%—
Financing activities10,151-2,298-2,78077
Financing changereported541.7%17.3%-3693.1%—
Net cash flowderived461-25331930
Free cash flowoperating + investing-9,6902,0453,098-47

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax2,8722,6732,3521,847
Income before WC changes4,1743,6693,3462,784
Change in Assets-328-29722-53
Change in Liabilities-14-18439635
Change in WC-342-481418-18
Cash flow from Operations3,0232,5853,2662,368
Cash flow from Investing-12,712-540-168-2,415
Cash flow from Financing10,151-2,298-2,78077
Total Cash Flow461-25331930
Cash (Start of the year)573835509398
Cash (End of the year)1,117573835509

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
60.78%
0.00 pts QoQ
FII
17.22%
-0.75 pts QoQ
DII (other)
4.64%
+0.05 pts QoQ
Mutual funds
8.82%
+0.55 pts QoQ
Retail & others
8.54%
+0.16 pts QoQ
Filed order
Promoters60.8%60.8%68.3%68.3%
FII17.2%18.0%15.4%16.2%
DII (other)4.6%4.6%4.9%4.6%
Mutual funds8.8%8.3%4.9%4.5%
Retail & others8.5%8.4%6.4%6.5%
Promoters — QoQ changepts, derived0.0%-7.5%0.0%—
FII — QoQ changepts, derived-0.8%2.5%-0.7%—
DII (other) — QoQ changepts, derived0.0%-0.3%0.3%—
Mutual funds — QoQ changepts, derived0.6%3.3%0.5%—
Retail & others — QoQ changepts, derived0.2%2.0%-0.0%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹9.00180.0%29 May 202629 May 202622 May 2026
DividendInterim₹29.00580.0%18 Feb 202619 Feb 202604 Feb 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.